Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential
Lysine-specific demethylase 1 (LSD1) is an enzyme that removes lysine methylation marks from nucleosome histone tails and plays an important role in cancer initiation, progression, metastasis, and recurrence. Recent research shows that LSD1 regulates tumor cells and immune cells through multiple ups...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1214675/full |
| _version_ | 1797785268285079552 |
|---|---|
| author | Lei Bao Lei Bao Ping Zhu Ping Zhu Yuan Mou Yuan Mou Yinhong Song Yinhong Song Yinhong Song Ye Qin Ye Qin |
| author_facet | Lei Bao Lei Bao Ping Zhu Ping Zhu Yuan Mou Yuan Mou Yinhong Song Yinhong Song Yinhong Song Ye Qin Ye Qin |
| author_sort | Lei Bao |
| collection | DOAJ |
| description | Lysine-specific demethylase 1 (LSD1) is an enzyme that removes lysine methylation marks from nucleosome histone tails and plays an important role in cancer initiation, progression, metastasis, and recurrence. Recent research shows that LSD1 regulates tumor cells and immune cells through multiple upstream and downstream pathways, enabling tumor cells to adapt to the tumor microenvironment (TME). As a potential anti-tumor treatment strategy, immunotherapy has developed rapidly in the past few years. However, most patients have a low response rate to available immune checkpoint inhibitors (ICIs), including anti-PD-(L)1 therapy and CAR-T cell therapy, due to a broad array of immunosuppressive mechanisms. Notably, inhibition of LSD1 turns “cold tumors” into “hot tumors” and subsequently enhances tumor cell sensitivity to ICIs. This review focuses on recent advances in LSD1 and tumor immunity and discusses a potential therapeutic strategy for combining LSD1 inhibition with immunotherapy. |
| first_indexed | 2024-03-13T00:52:37Z |
| format | Article |
| id | doaj.art-d4141acbf0314bf68e863faa82c7c657 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-13T00:52:37Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-d4141acbf0314bf68e863faa82c7c6572023-07-07T12:07:16ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-07-011410.3389/fimmu.2023.12146751214675Targeting LSD1 in tumor immunotherapy: rationale, challenges and potentialLei Bao0Lei Bao1Ping Zhu2Ping Zhu3Yuan Mou4Yuan Mou5Yinhong Song6Yinhong Song7Yinhong Song8Ye Qin9Ye Qin10Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, ChinaCollege of Basic Medical Science, China Three Gorges University, Yichang, ChinaDepartment of Nephrology, The First College of Clinical Medical Science, China Three Gorges University, Yichang, ChinaInstitute of Infection and Inflammation, China Three Gorges University, Yichang, ChinaHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, ChinaCollege of Basic Medical Science, China Three Gorges University, Yichang, ChinaHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, ChinaCollege of Basic Medical Science, China Three Gorges University, Yichang, ChinaInstitute of Infection and Inflammation, China Three Gorges University, Yichang, ChinaHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, ChinaCollege of Basic Medical Science, China Three Gorges University, Yichang, ChinaLysine-specific demethylase 1 (LSD1) is an enzyme that removes lysine methylation marks from nucleosome histone tails and plays an important role in cancer initiation, progression, metastasis, and recurrence. Recent research shows that LSD1 regulates tumor cells and immune cells through multiple upstream and downstream pathways, enabling tumor cells to adapt to the tumor microenvironment (TME). As a potential anti-tumor treatment strategy, immunotherapy has developed rapidly in the past few years. However, most patients have a low response rate to available immune checkpoint inhibitors (ICIs), including anti-PD-(L)1 therapy and CAR-T cell therapy, due to a broad array of immunosuppressive mechanisms. Notably, inhibition of LSD1 turns “cold tumors” into “hot tumors” and subsequently enhances tumor cell sensitivity to ICIs. This review focuses on recent advances in LSD1 and tumor immunity and discusses a potential therapeutic strategy for combining LSD1 inhibition with immunotherapy.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1214675/fullLSD1immunotherapyPD-(L)1tumor microenvironmentcombination therapy |
| spellingShingle | Lei Bao Lei Bao Ping Zhu Ping Zhu Yuan Mou Yuan Mou Yinhong Song Yinhong Song Yinhong Song Ye Qin Ye Qin Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential Frontiers in Immunology LSD1 immunotherapy PD-(L)1 tumor microenvironment combination therapy |
| title | Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential |
| title_full | Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential |
| title_fullStr | Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential |
| title_full_unstemmed | Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential |
| title_short | Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential |
| title_sort | targeting lsd1 in tumor immunotherapy rationale challenges and potential |
| topic | LSD1 immunotherapy PD-(L)1 tumor microenvironment combination therapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1214675/full |
| work_keys_str_mv | AT leibao targetinglsd1intumorimmunotherapyrationalechallengesandpotential AT leibao targetinglsd1intumorimmunotherapyrationalechallengesandpotential AT pingzhu targetinglsd1intumorimmunotherapyrationalechallengesandpotential AT pingzhu targetinglsd1intumorimmunotherapyrationalechallengesandpotential AT yuanmou targetinglsd1intumorimmunotherapyrationalechallengesandpotential AT yuanmou targetinglsd1intumorimmunotherapyrationalechallengesandpotential AT yinhongsong targetinglsd1intumorimmunotherapyrationalechallengesandpotential AT yinhongsong targetinglsd1intumorimmunotherapyrationalechallengesandpotential AT yinhongsong targetinglsd1intumorimmunotherapyrationalechallengesandpotential AT yeqin targetinglsd1intumorimmunotherapyrationalechallengesandpotential AT yeqin targetinglsd1intumorimmunotherapyrationalechallengesandpotential |